Inovio Pharmas and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial

PLYMOUTH MEETING, PA  – June 20, 2016 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} and GeneOne Life Science, Inc. (KSE: 011000) today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700) to prevent infection from this concerning virus. Continue reading